Bone Marrow Transplant Rejection – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bone Marrow Transplant Rejection – Pipeline Review, H2 2016’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection

The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AbGenomics International, Inc.

Actelion Ltd

Alexion Pharmaceuticals Inc

Amunix Operating Inc.

Apceth GmbH & Co. KG

arGEN-X BV

Athersys, Inc.

Bellicum Pharmaceuticals, Inc.

Bio-Cancer Treatment International Limited

Biogen Inc

Boryung Pharmaceutical Co., Ltd.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Capricor Therapeutics, Inc.

Cell Source, Inc.

Cell2B S.A.

CellECT Bio, Inc.

Cleveland BioLabs, Inc.

Compugen Ltd.

Cynata Therapeutics Limited

Cytodyn Inc.

Dompe Farmaceutici S.p.A.

Dr. Falk Pharma GmbH

Escape Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Fate Therapeutics, Inc.

Generon (Shanghai) Corporation Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

ImmuNext, Inc.

Immunomedics, Inc.

Incyte Corporation

Kadmon Corporation, LLC

Kamada Ltd.

Kiadis Pharma N.V.

Kymab Limited

Kyorin Pharmaceutical Co., Ltd.

MacroGenics, Inc.

Mallinckrodt Plc

Medsenic

Mesoblast Limited

Millennium Pharmaceuticals Inc

Neopharm Ltd.

Nohla Therapeutics Inc.

Novartis AG

OncoImmune, Inc.

OSE Immunotherapeutics

Pharmicell Co., Ltd.

Pluristem Therapeutics Inc.

REGiMMUNE Corporation

Rigel Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Seattle Genetics, Inc.

Seres Therapeutics, Inc.

Sigmoid Pharma Limited

Spherium Biomed S.L.

Taiga Biotechnologies, Inc.

Takeda Pharmaceutical Company Limited

Targazyme, Inc.

Therapix Biosciences Ltd

Tobira Therapeutics, Inc.

Vault Pharma Inc.

Xenikos B.V.

ZIOPHARM Oncology, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Bone Marrow Transplant Rejection Overview 11

Therapeutics Development 12

Pipeline Products for Bone Marrow Transplant Rejection - Overview 12

Pipeline Products for Bone Marrow Transplant Rejection - Comparative Analysis 13

Bone Marrow Transplant Rejection - Therapeutics under Development by Companies 14

Bone Marrow Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 19

Bone Marrow Transplant Rejection - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Bone Marrow Transplant Rejection - Products under Development by Companies 25

Bone Marrow Transplant Rejection - Products under Investigation by Universities/Institutes 31

Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 33

AbbVie Inc 33

AbGenomics International, Inc. 34

Actelion Ltd 35

Alexion Pharmaceuticals Inc 36

Amunix Operating Inc. 37

Apceth GmbH & Co. KG 38

arGEN-X BV 39

Athersys, Inc. 40

Bellicum Pharmaceuticals, Inc. 41

Bio-Cancer Treatment International Limited 42

Biogen Inc 43

Boryung Pharmaceutical Co., Ltd. 44

Bristol-Myers Squibb Company 45

Cantex Pharmaceuticals, Inc. 46

Capricor Therapeutics, Inc. 47

Cell Source, Inc. 48

Cell2B S.A. 49

CellECT Bio, Inc. 50

Cleveland BioLabs, Inc. 51

Compugen Ltd. 52

Cynata Therapeutics Limited 53

Cytodyn Inc. 54

Dompe Farmaceutici S.p.A. 55

Dr. Falk Pharma GmbH 56

Escape Therapeutics, Inc. 57

F. Hoffmann-La Roche Ltd. 58

Fate Therapeutics, Inc. 59

Generon (Shanghai) Corporation Ltd. 60

Gilead Sciences, Inc. 61

GlaxoSmithKline Plc 62

Idera Pharmaceuticals, Inc. 63

ImmuNext, Inc. 64

Immunomedics, Inc. 65

Incyte Corporation 66

Kadmon Corporation, LLC 67

Kamada Ltd. 68

Kiadis Pharma N.V. 69

Kymab Limited 70

Kyorin Pharmaceutical Co., Ltd. 71

MacroGenics, Inc. 72

Mallinckrodt Plc 73

Medsenic 74

Mesoblast Limited 75

Millennium Pharmaceuticals Inc 76

Neopharm Ltd. 77

Nohla Therapeutics Inc. 78

Novartis AG 79

OncoImmune, Inc. 80

OSE Immunotherapeutics 81

Pharmicell Co., Ltd. 82

Pluristem Therapeutics Inc. 83

REGiMMUNE Corporation 84

Rigel Pharmaceuticals, Inc. 85

Sarepta Therapeutics, Inc. 86

Seattle Genetics, Inc. 87

Seres Therapeutics, Inc. 88

Sigmoid Pharma Limited 89

Spherium Biomed S.L. 90

Taiga Biotechnologies, Inc. 91

Takeda Pharmaceutical Company Limited 92

Targazyme, Inc. 93

Therapix Biosciences Ltd 94

Tobira Therapeutics, Inc. 95

Vault Pharma Inc. 96

Xenikos B.V. 97

ZIOPHARM Oncology, Inc. 98

Bone Marrow Transplant Rejection - Therapeutics Assessment 99

Assessment by Monotherapy Products 99

Assessment by Combination Products 100

Assessment by Target 101

Assessment by Mechanism of Action 105

Assessment by Route of Administration 109

Assessment by Molecule Type 111

Drug Profiles 113

abatacept - Drug Profile 113

AbGn-168H - Drug Profile 118

AGS-499 - Drug Profile 120

aldesleukin - Drug Profile 121

Alecmestencel-L - Drug Profile 123

alpha-1 proteinase inhibitor (human) - Drug Profile 124

ALXN-1007 - Drug Profile 129

AMX-342 - Drug Profile 130

anti-thymocyte globulin (rabbit) - Drug Profile 131

Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 133

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 134

ARGX-115 - Drug Profile 135

arsenic trioxide - Drug Profile 136

ATIR-101 - Drug Profile 137

BCT-200 - Drug Profile 141

begelomab - Drug Profile 142

Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 143

Biologics for Graft Versus Host Disease - Drug Profile 144

bortezomib - Drug Profile 145

BPX-501 - Drug Profile 153

BR-05001 - Drug Profile 157

brentuximab vedotin - Drug Profile 158

budesonide - Drug Profile 182

cannabidiol - Drug Profile 185

CAP-2003 - Drug Profile 186

CBLB-612 - Drug Profile 187

CD-24Fc - Drug Profile 189

Cell Therapy for Graft Versus Host Disease - Drug Profile 190

Cell Therapy for Graft-Versus Host Disease - Drug Profile 191

Cellgram for Graft Versus Host Disease - Drug Profile 192

Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 193

Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 194

Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 196

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 197

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 198

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 199

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 200

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 201

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 202

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 203

Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 204

cenicriviroc mesylate - Drug Profile 205

CGEN-15001 - Drug Profile 212

CRCBT-080004 - Drug Profile 215

CX-01 - Drug Profile 216

cyclosporine CR + cyclosporine IR - Drug Profile 218

CYP-001 - Drug Profile 219

entospletinib - Drug Profile 220

F-652 - Drug Profile 222

FR-104 - Drug Profile 223

Ha-7 - Drug Profile 226

ibrutinib - Drug Profile 227

ImmuneSafe - Drug Profile 252

ImmuStem - Drug Profile 253

IMO-8400 - Drug Profile 254

IT-603 - Drug Profile 260

IT-901 - Drug Profile 261

itacitinib adipate - Drug Profile 262

KD-025 - Drug Profile 265

KRP-203 - Drug Profile 269

KY-1005 - Drug Profile 271

MAX-16H5 - Drug Profile 272

MesoStem - Drug Profile 273

methoxsalen - Drug Profile 274

MGD-010 - Drug Profile 276

milatuzumab - Drug Profile 278

Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 281

MPC-CBE - Drug Profile 283

natalizumab - Drug Profile 285

obinutuzumab - Drug Profile 290

OCU-300 - Drug Profile 297

Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 298

panobinostat - Drug Profile 299

PF-05285401 - Drug Profile 307

PLXR-18 - Drug Profile 318

ponesimod - Drug Profile 325

Preimplantation Factor - Drug Profile 328

PRO-140 - Drug Profile 329

ProTmune - Drug Profile 337

R-348 - Drug Profile 339

Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 341

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 342

Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 343

remestemcel-L - Drug Profile 344

reparixin - Drug Profile 349

RGI-2001 - Drug Profile 352

RO-2959 - Drug Profile 354

rovalpituzumab tesirine - Drug Profile 355

ruxolitinib phosphate - Drug Profile 357

S-Graft - Drug Profile 370

SER-155 - Drug Profile 371

Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 372

Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 373

Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 374

Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 375

Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 376

sonidegib phosphate - Drug Profile 377

SP-12008 - Drug Profile 382

SYGN-305 - Drug Profile 383

Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 384

T-Guard - Drug Profile 385

TBX-1400 - Drug Profile 387

TM-5509 - Drug Profile 388

TZ-101 - Drug Profile 389

vedolizumab - Drug Profile 392

VPI-101 - Drug Profile 397

ZL-1101 - Drug Profile 398

Bone Marrow Transplant Rejection - Dormant Projects 399

Bone Marrow Transplant Rejection - Discontinued Products 405

Bone Marrow Transplant Rejection - Product Development Milestones 406

Featured News & Press Releases 406

Appendix 418

Methodology 418

Coverage 418

Secondary Research 418

Primary Research 418

Expert Panel Validation 418

Contact Us 418

Disclaimer 419

List of Tables

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20

Number of Products under Development for Bone Marrow Transplant Rejection – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Development by Companies, H2 2016 (Contd..1) 23

Number of Products under Development by Companies, H2 2016 (Contd..2) 24

Number of Products under Development by Companies, H2 2016 (Contd..3) 25

Number of Products under Development by Companies, H2 2016 (Contd..4) 26

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Development, H2 2016 31

Comparative Analysis by Unknown Stage Development, H2 2016 32

Products under Development by Companies, H2 2016 33

Products under Development by Companies, H2 2016 (Contd..1) 34

Products under Development by Companies, H2 2016 (Contd..2) 35

Products under Development by Companies, H2 2016 (Contd..3) 36

Products under Development by Companies, H2 2016 (Contd..4) 37

Products under Development by Companies, H2 2016 (Contd..5) 38

Products under Investigation by Universities/Institutes, H2 2016 39

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40

Bone Marrow Transplant Rejection – Pipeline by AbbVie Inc, H2 2016 41

Bone Marrow Transplant Rejection – Pipeline by AbGenomics International, Inc., H2 2016 42

Bone Marrow Transplant Rejection – Pipeline by Actelion Ltd, H2 2016 43

Bone Marrow Transplant Rejection – Pipeline by Alexion Pharmaceuticals Inc, H2 2016 44

Bone Marrow Transplant Rejection – Pipeline by Amunix Operating Inc. , H2 2016 45

Bone Marrow Transplant Rejection – Pipeline by Apceth GmbH & Co. KG, H2 2016 46

Bone Marrow Transplant Rejection – Pipeline by arGEN-X BV, H2 2016 47

Bone Marrow Transplant Rejection – Pipeline by Athersys, Inc., H2 2016 48

Bone Marrow Transplant Rejection – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 49

Bone Marrow Transplant Rejection – Pipeline by Bio-Cancer Treatment International Limited, H2 2016 50

Bone Marrow Transplant Rejection – Pipeline by Biogen Inc, H2 2016 51

Bone Marrow Transplant Rejection – Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016 52

Bone Marrow Transplant Rejection – Pipeline by Bristol-Myers Squibb Company, H2 2016 53

Bone Marrow Transplant Rejection – Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 54

Bone Marrow Transplant Rejection – Pipeline by Capricor Therapeutics, Inc., H2 2016 55

Bone Marrow Transplant Rejection – Pipeline by Cell Source, Inc., H2 2016 56

Bone Marrow Transplant Rejection – Pipeline by Cell2B S.A. , H2 2016 57

Bone Marrow Transplant Rejection – Pipeline by CellECT Bio, Inc., H2 2016 58

Bone Marrow Transplant Rejection – Pipeline by Cleveland BioLabs, Inc., H2 2016 59

Bone Marrow Transplant Rejection – Pipeline by Compugen Ltd., H2 2016 60

Bone Marrow Transplant Rejection – Pipeline by Cynata Therapeutics Limited, H2 2016 61

Bone Marrow Transplant Rejection – Pipeline by Cytodyn Inc., H2 2016 62

Bone Marrow Transplant Rejection – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 63

Bone Marrow Transplant Rejection – Pipeline by Dr. Falk Pharma GmbH, H2 2016 64

Bone Marrow Transplant Rejection – Pipeline by Escape Therapeutics, Inc., H2 2016 65

Bone Marrow Transplant Rejection – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 66

Bone Marrow Transplant Rejection – Pipeline by Fate Therapeutics, Inc., H2 2016 67

Bone Marrow Transplant Rejection – Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 68

Bone Marrow Transplant Rejection – Pipeline by Gilead Sciences, Inc., H2 2016 69

Bone Marrow Transplant Rejection – Pipeline by GlaxoSmithKline Plc, H2 2016 70

Bone Marrow Transplant Rejection – Pipeline by Idera Pharmaceuticals, Inc., H2 2016 71

Bone Marrow Transplant Rejection – Pipeline by ImmuNext, Inc., H2 2016 72

Bone Marrow Transplant Rejection – Pipeline by Immunomedics, Inc., H2 2016 73

Bone Marrow Transplant Rejection – Pipeline by Incyte Corporation, H2 2016 74

Bone Marrow Transplant Rejection – Pipeline by Kadmon Corporation, LLC, H2 2016 75

Bone Marrow Transplant Rejection – Pipeline by Kamada Ltd., H2 2016 76

Bone Marrow Transplant Rejection – Pipeline by Kiadis Pharma N.V., H2 2016 77

Bone Marrow Transplant Rejection – Pipeline by Kymab Limited, H2 2016 78

Bone Marrow Transplant Rejection – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 79

Bone Marrow Transplant Rejection – Pipeline by MacroGenics, Inc., H2 2016 80

Bone Marrow Transplant Rejection – Pipeline by Mallinckrodt Plc, H2 2016 81

Bone Marrow Transplant Rejection – Pipeline by Medsenic, H2 2016 82

Bone Marrow Transplant Rejection – Pipeline by Mesoblast Limited, H2 2016 83

Bone Marrow Transplant Rejection – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 84

Bone Marrow Transplant Rejection – Pipeline by Neopharm Ltd., H2 2016 85

Bone Marrow Transplant Rejection – Pipeline by Nohla Therapeutics Inc., H2 2016 86

Bone Marrow Transplant Rejection – Pipeline by Novartis AG, H2 2016 87

Bone Marrow Transplant Rejection – Pipeline by OncoImmune, Inc., H2 2016 88

Bone Marrow Transplant Rejection – Pipeline by OSE Immunotherapeutics, H2 2016 89

Bone Marrow Transplant Rejection – Pipeline by Pharmicell Co., Ltd., H2 2016 90

Bone Marrow Transplant Rejection – Pipeline by Pluristem Therapeutics Inc., H2 2016 91

Bone Marrow Transplant Rejection – Pipeline by REGiMMUNE Corporation, H2 2016 92

Bone Marrow Transplant Rejection – Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 93

Bone Marrow Transplant Rejection – Pipeline by Sarepta Therapeutics, Inc., H2 2016 94

Bone Marrow Transplant Rejection – Pipeline by Seattle Genetics, Inc., H2 2016 95

Bone Marrow Transplant Rejection – Pipeline by Seres Therapeutics, Inc., H2 2016 96

Bone Marrow Transplant Rejection – Pipeline by Sigmoid Pharma Limited, H2 2016 97

Bone Marrow Transplant Rejection – Pipeline by Spherium Biomed S.L., H2 2016 98

Bone Marrow Transplant Rejection – Pipeline by Taiga Biotechnologies, Inc., H2 2016 99

Bone Marrow Transplant Rejection – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 100

Bone Marrow Transplant Rejection – Pipeline by Targazyme, Inc., H2 2016 101

Bone Marrow Transplant Rejection – Pipeline by Therapix Biosciences Ltd, H2 2016 102

Bone Marrow Transplant Rejection – Pipeline by Tobira Therapeutics, Inc., H2 2016 103

Bone Marrow Transplant Rejection – Pipeline by Vault Pharma Inc., H2 2016 104

Bone Marrow Transplant Rejection – Pipeline by Xenikos B.V., H2 2016 105

Bone Marrow Transplant Rejection – Pipeline by ZIOPHARM Oncology, Inc., H2 2016 106

Assessment by Monotherapy Products, H2 2016 107

Assessment by Combination Products, H2 2016 108

Number of Products by Stage and Target, H2 2016 110

Number of Products by Stage and Mechanism of Action, H2 2016 114

Number of Products by Stage and Route of Administration, H2 2016 118

Number of Products by Stage and Molecule Type, H2 2016 120

Bone Marrow Transplant Rejection – Dormant Projects, H2 2016 406

Bone Marrow Transplant Rejection – Dormant Projects (Contd..1), H2 2016 407

Bone Marrow Transplant Rejection – Dormant Projects (Contd..2), H2 2016 408

Bone Marrow Transplant Rejection – Dormant Projects (Contd..3), H2 2016 409

Bone Marrow Transplant Rejection – Dormant Projects (Contd..4), H2 2016 410

Bone Marrow Transplant Rejection – Dormant Projects (Contd..5), H2 2016 411

Bone Marrow Transplant Rejection – Discontinued Products, H2 2016 412

List of Figures

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20

Number of Products under Development for Bone Marrow Transplant Rejection – Comparative Analysis, H2 2016 21

Number of Products under Development by Companies, H2 2016 22

Number of Products under Investigation by Universities/Institutes, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Products, H2 2016 31

Assessment by Monotherapy Products, H2 2016 107

Number of Products by Top 10 Targets, H2 2016 109

Number of Products by Stage and Top 10 Targets, H2 2016 109

Number of Products by Top 10 Mechanism of Actions, H2 2016 113

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 113

Number of Products by Top 10 Routes of Administration, H2 2016 117

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 117

Number of Products by Top 10 Molecule Types, H2 2016 119

Number of Products by Stage and Top 10 Molecule Types, H2 2016 119

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports